Skip to Content

Acasti Pharma Inc

Rating as of

Company Profile

Business Description

Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia.

Contact
545, Promenade du Centropolis, Suite 100
Laval, QC, H7T 0A3, Canada
T +1 450 686-4555
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2019
Fiscal Year End Mar 31, 2020
Stock Type
Employees 28